---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-22-044592"
form_type: "8-K"
ticker: "ADMA"
cik: "0001368514"
company_name: "ADMA BIOLOGICS, INC."
filed_at: "2022-12-06T23:59:59+00:00"
generated_at: "2026-06-21T08:44:26.828406+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ADMA Biologics prelim Q4 revenue ~$48-50M (+85% YoY); launches public stock offering

## Summary
- Preliminary Q4 2022 revenue $48-50M, up >85% YoY from $26.4M; full-year revenue $152-154M.
- Launches underwritten public offering of common stock; 30-day option for additional 15% of shares.
- Strategic review continues; received non-binding offers but board determined insufficient value.
- Expects positive cash flow from operations by Q1 2024; may require additional capital.
- Proceeds to accelerate commercialization, production, and plasma center buildout.

## SEC filing metadata
- accession: 0001140361-22-044592
- form_type: 8-K
- ticker: ADMA
- cik: 0001368514
- company_name: ADMA BIOLOGICS, INC.
- filed_at: 2022-12-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1368514/000114036122044592/0001140361-22-044592-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1368514/000114036122044592/ny20006122x2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-22-044592
- JSON: https://secwatch.observer/filing/0001140361-22-044592.json
- Plain text: https://secwatch.observer/filing/0001140361-22-044592.txt

## Key facts
- Earnings Releases
  ADMA BIOLOGICS, INC. reported year-ended December 31, 2022 results: revenue between $152 million and $154 million.
  - Period: year-ended December 31, 2022
  - Revenue: between $152 million and $154 million
  - Result: preliminary results
  source text: ADMA preliminarily estimates that its total revenue for the quarter- and year-ended December 31, 2022 will be between $48 million and $50 million and $152 million and $154 million, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1368514/000114036122044592/0001140361-22-044592-index.htm
- Earnings Releases
  ADMA BIOLOGICS, INC. reported quarter-ended December 31, 2022 results: revenue between $48 million and $50 million.
  - Period: quarter-ended December 31, 2022
  - Revenue: between $48 million and $50 million
  - Result: preliminary results
  source text: ADMA preliminarily estimates that its total revenue for the quarter- and year-ended December 31, 2022 will be between $48 million and $50 million and $152 million and $154 million, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1368514/000114036122044592/0001140361-22-044592-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.